Divi’s Laboratories, a player in the pharmaceutical industry, has officially commenced commercial operations at its Unit III greenfield project in Kakinada, Andhra Pradesh.
The facility became operational on January 1, 2025, marking a significant step in the company’s journey to enhance its manufacturing capabilities.
Strategic Location and Investment in Phase I
Unit III is strategically situated on a sprawling 500 acre site in Kakinada.
The initial phase of the project spans 200 acres and involved an investment of approximately ₹1,200 crore to ₹1,500 crore.
The large-scale development aligns with Divi’s commitment to meeting the increasing global demand for pharmaceutical products.
Boosting Production Capacity
The newly operational facility will play a pivotal role in expanding the company’s production capacity.
Unit III boasts advanced infrastructure and a strategic location. It aims to strengthen Divi’s Laboratories’ position as a leading player in the global pharmaceutical market.
Expertise in APIs and Global Reach
Divi’s Laboratories specializes in active pharmaceutical ingredients (APIs) and intermediates, catering to a diverse clientele across multiple regions.
The launch of Unit III underscores the company’s dedication to innovation, quality, and sustained growth in the pharmaceutical sector.
As reported by projectstoday.com, the milestone highlights Divi’s Laboratories’ ongoing efforts. The company continues to adapt to evolving industry demands and maintain its leadership in the global market.
